You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03094052 ↗ Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Recruiting Napo Pharmaceuticals, Inc. Phase 2 2018-10-09 This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
NCT03094052 ↗ Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Recruiting Puma Biotechnology, Inc. Phase 2 2018-10-09 This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
NCT03094052 ↗ Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Recruiting University of California, San Francisco Phase 2 2018-10-09 This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Condition Name

Condition Name for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Intervention Trials
Breast Adenocarcinoma 1
HER2-positive Breast Cancer 1
Stage II Breast Cancer AJCC v6 and v7 1
Stage IIA Breast Cancer AJCC v6 and v7 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Intervention Trials
Diarrhea 1
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Trials by Country

Trials by Country for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Location Trials
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Clinical Trial Phase

Clinical Trial Phase for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Clinical Trial Phase Trials
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

Sponsor Name

Sponsor Name for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Sponsor Trials
Napo Pharmaceuticals, Inc. 1
Puma Biotechnology, Inc. 1
University of California, San Francisco 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Sponsor Trials
Industry 2
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.